Anti-VEGF therapy in the management of retinopathy of prematurity: what we learn from representative animal models of oxygen-induced retinopathy
Haibo Wang Department of Ophthalmology, John A Moran Eye Center, The University of Utah, Salt Lake City, UT, USA Abstract: Retinopathy of prematurity (ROP) remains a leading cause of childhood blindness, affecting infants born prematurely. ROP is characterized by the onset of delayed physiological...
Main Author: | Wang H |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2016-05-01
|
Series: | Eye and Brain |
Subjects: | |
Online Access: | https://www.dovepress.com/anti-vegf-therapy-in-the-management-of-retinopathy-of-prematurity-what-peer-reviewed-article-EB |
Similar Items
-
Researches advance on anti-VEGF medication for retinopathy of prematurity
by: Huan-Huan Zhao, et al.
Published: (2013-12-01) -
The progress of prophylactic treatment in retinopathy of prematurity
by: Hong-Bing Zhang, et al.
Published: (2018-05-01) -
Effect of Probenecid on Endothelial Cell Growth Rate and Retinal Angiogenesis in an Oxygen-Induced Retinopathy Model
by: Jingbo Jiang, et al.
Published: (2021-10-01) -
Promotion effect and mechanism of Caspase-1 on microglia in retinal neovascularization in oxygen-induced retinopathy
by: Zhi-Cha Hu, et al.
Published: (2018-04-01) -
Anti-VEGF therapy in retinopathy of prematurity
by: Qin Peng, et al.
Published: (2020-11-01)